How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/complicated-skin-and-skin-structure-e-coli-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Complicated Skin and Skin Structure E. Coli Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complicated Skin and Skin Structure E. Coli Infection (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Complicated Skin and Skin Structure E. Coli Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tygacil	TIGECYCLINE	Fresenius Kabi	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	2005-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Avelox	Avelox	Novartis Pharmaceuticals		DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Complicated Skin and Skin Structure E. Coli Infection
Bayer AG · 1 drug in Complicated Skin and Skin Structure E. Coli Infection
Fresenius Kabi · 1 drug in Complicated Skin and Skin Structure E. Coli Infection
Merck & Co. · 1 drug in Complicated Skin and Skin Structure E. Coli Infection
Novartis Pharmaceuticals · 1 drug in Complicated Skin and Skin Structure E. Coli Infection
Pfizer · 1 drug in Complicated Skin and Skin Structure E. Coli Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Complicated Skin and Skin Structure E. Coli Infection:

Cite this brief

Drug Landscape (2026). Complicated Skin and Skin Structure E. Coli Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-skin-and-skin-structure-e-coli-infection. Accessed 2026-06-10.

Complicated Skin and Skin Structure E. Coli Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing